Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Head of Central Nervous System Disease Therapy Area

Build a management team with global and local experience and expertise to enable rapid execution of the company’s broad therapeutic strategy

DURHAM, North Carolina and BEIJING, August 22, 2022 /PRNewswire/ — Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK), a multinational company developing innovative therapies for diseases with high unmet medical needs and significant burdens public health, today announced the appointments of Eleanor (Ellee) de GrootPh.D., as Chief Technology Officer and Alexander SkubanMD, as head of the central nervous system (CNS) disease therapy area.

“Ellee and Aleksandar are both seasoned biotech leaders with impressive credentials and entrepreneurial histories in drug development and manufacturing initiatives in their functional areas. We are delighted to welcome them to the Brii Bio team as we continue to advance our pipeline of innovative drug candidates. on behalf of patients facing important health challenges around the world,” said Zhi Hong, Ph.D., Chairman and CEO of Brii Bio. “With experience spanning all phases of drug manufacturing, Ellee is an important addition to our leadership team as we execute our broad therapeutic modalities. Prioritize the advancement of our major US therapeutic programs in postpartum depression and major depressive and anxiety disorders. »

Eleanor (Ellee) de GrootPh.D., Chief Technology Officer

Dr. de Groot has more than two decades of experience leading a wide range of streamlined global operations at growing biotechnology companies, from early to late-stage clinical development and commercial-scale manufacturing. . Dr. de Groot has held key leadership positions during her career at Alaunos Therapeutics, most recently as Executive Vice President of Operations, where she oversaw the development of novel cell therapy programs and led clinical manufacturing, quality and process development. Additionally, during her extended tenure at Helsinn Therapeutics, Dr. de Groot held several positions of increasing responsibility within the leadership of CMC, where she led preparations for the commercialization of pharmaceutical products, including engagement global regulatory framework, technology transfers and collaborations with key business partners around the world. Dr. de Groot holds both a Ph.D. and Master of Science in Chemical Engineering from Stanford Universitya Bachelor of Science in Chemical Engineering from Massachusetts Institute of Technology (MIT) and a Masters in Business Administration from rice university.

“I believe Brii Bio’s diverse pipeline of promising therapeutic candidates holds great potential to address some of the greatest public health challenges of our time, and I look forward to contributing my expertise to support ongoing product development.” and generate a long-term sustainable growth strategy. within the Company,” said Elle de GrootPh.D., Chief Technology Officer of Brii Bio.

Alexander SkubanMD, CNS Disease Therapy Area Leader

Dr. Skuban brings to Brii Bio over 25 years of global pharmaceutical R&D experience with an extensive track record of achievement in medical, scientific and business leadership, including leading over 30 studies in therapeutic areas, from early-stage proof-of-concept to positive regulatory results, with a focus on CNS diseases. Previously, Dr. Skuban served as Senior Vice President of Clinical Development at Better Therapeutics, where he shaped research strategy to enable the rapid development of new indications for digital prescription therapies. Previously, he served as Executive Medical Director, leading clinical development within Alexion’s emerging ophthalmology therapeutic area. At Otsuka Pharmaceuticals, Dr. Skuban’s tenure included roles overseeing various clinical portfolios, including guiding the FDA approval of brexpiprazole (REXULTI) for major depressive disorder and schizophrenia. Dr. Skuban has also held several clinical development director positions at Merck and Sanofi-Aventis. He obtained a doctorate in medicine from the Semmelweis Medical University, Budapest, Hungary and attended Novi Sad University School of Medicine, Novi Sad, Yugoslavia (Serbia).

“I am inspired by the meaningful patient-centric approach that Brii Bio has cultivated in the early stages of clinical planning. I look forward to incorporating unique patient insights into Brii’s CNS programs to ensure that our experimental treatments are well positioned for the future of mental health care and based on fundamental understanding of patient preferences and needs,” said Alexander SkubanMD, Head of Brii Bio’s CNS Disease Therapy Area.

About Brii Bio

Brii Biosciences Limited (“Brii Bio”, stock code: 2137.HK) is a biotechnology company based in China and United States committed to advancing therapies for important infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multidrug-resistant (MDR) or extensive Gram-negative infections drug-resistant (XDR), and other diseases, such as central nervous system (CNS) diseases, which pose a heavy public health burden China and around the world. For more information, visit

SOURCE Brii Biosciences Limited

Back To Top